A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic andPharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection ofRecombinant Humanized Anti‐CD20 Monoclonal Antibody in the Treatment of PrimaryMembranous Nephropathy
Epistemonikos ID: b9c696591d92b3b6c6ec15cd64b4724dc968ba01
First added on: May 14, 2024